Sign inJoin
Company / Finance

ADC Therapeutics SA

ADCT · NYSE

ADCT already sells ZYNLONTA, but the story is not solved by having revenue. The next question is whether the 2026 lymphoma data can widen the drug's role before cash burn, royalties, debt, and dilution take the lead.

FollowAdd to WatchlistAsk Question
NYSEADCTCoverage BootstrapBiotechnologyOncologyAntibody Drug Conjugates
Latest ReportMay 14, 2026ADC Therapeutics: the lymphoma readout trying to beat the royalty wallView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 company reports
Latest Thesis

ADC Therapeutics: the lymphoma readout trying to beat the royalty wall

ADCT already sells ZYNLONTA, but the story is not solved by having revenue. The next question is whether the 2026 lymphoma data can widen the drug's role before cash burn, royalties, debt, and dilution take the lead.

May 14, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
ADC Therapeutics SATherapeutics: the lymphoma readout trying to beat the royalty waMay 14, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
ADC Therapeutics: the lymphoma readout trying to beat the royalty wallADCT already sells ZYNLONTA, but the story is not solved by having revenue. The next question is whether the 2026 lymphoma data can widen the drug's role before cash burn, royalties, debt, and dilution take the lead.NYSEMay 14, 2026Research reportReadSlides